↓ Skip to main content

Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.

Overview of attention for article published in Journal of Rheumatology, December 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Readers on

mendeley
99 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.
Published in
Journal of Rheumatology, December 2009
DOI 10.3899/jrheum.090817
Pubmed ID
Authors

Philip J Mease, Nathan Wei, Edward J Fudman, Alan J Kivitz, Joy Schechtman, Robert G Trapp, Kathryn F Hobbs, Maria Greenwald, Antony Hou, Stephen A Bookbinder, Galen E Graham, Craig W Wiesenhutter, Larry Willis, Eric M Ruderman, Joseph Z Forstot, Michael J Maricic, Kathryn H Dao, Charles H Pritchard, Darrell N Fiske, Francis X Burch, H Malin Prupas, Pervin Anklesaria, Alison E Heald

Abstract

To assess safety and clinical outcomes in patients with inflammatory arthritis after intraarticular (IA) injection of rAAV2-TNFR:Fc, a recombinant adeno-associated viral vector containing the human tumor necrosis factor (TNF) receptor-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Colombia 1 1%
Portugal 1 1%
Norway 1 1%
Unknown 95 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 20 20%
Researcher 15 15%
Other 9 9%
Student > Bachelor 8 8%
Student > Doctoral Student 7 7%
Other 22 22%
Unknown 18 18%
Readers by discipline Count As %
Medicine and Dentistry 33 33%
Agricultural and Biological Sciences 11 11%
Biochemistry, Genetics and Molecular Biology 10 10%
Pharmacology, Toxicology and Pharmaceutical Science 9 9%
Nursing and Health Professions 6 6%
Other 12 12%
Unknown 18 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 June 2022.
All research outputs
#4,837,286
of 25,377,790 outputs
Outputs from Journal of Rheumatology
#988
of 3,951 outputs
Outputs of similar age
#25,668
of 172,607 outputs
Outputs of similar age from Journal of Rheumatology
#4
of 29 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,951 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,607 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.